Apogee Therapeutics (APGE) Return on Capital Employed (2023 - 2026)
Apogee Therapeutics (APGE) posted quarterly Return on Capital Employed of 28.2% for Q1 2026, up 628.0% year-over-year from 3.87% in Q1 2025, and up 25.57% quarter-over-quarter from 37.89% in Q4 2025.
Apogee Therapeutics (APGE) Return on Capital Employed (2023 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has reported Return on Capital Employed for 4 consecutive years, with 28.2% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 628.0% year-over-year to 28.2%; the TTM figure through Mar 2026 stood at 28.2% (up 628.0% YoY), while the FY2025 annual figure was 34.93%, up 456.0% from the prior year.
- Return on Capital Employed advanced to 28.2% in Q1 2026 per APGE's latest filing, from 37.89% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 18.25% in Q2 2024 and bottomed at 46.62% in Q3 2025.
- Historically, Return on Capital Employed has averaged 30.03% across 4 years, with a median of 28.2% in 2026.
- Annual changes were most pronounced in 2025 — Return on Capital Employed slumped 2313 bps — and 2026, when it surged 628 bps.
- Apogee Therapeutics' Return on Capital Employed stood at 23.64% in 2023, then slipped by 25 bps to 29.44% in 2024, then decreased by 29 bps to 37.89% in 2025, then increased by 26 bps to 28.2% in 2026.
- Business Quant data shows APGE's Return on Capital Employed at 28.2% in Q1 2026, 37.89% in Q4 2025, and 46.62% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Apogee Therapeutics | 10.14 Bn | 9.16 Bn | - | -25.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.69% |
| Mar 31, 2026 | -28.20% |
| Dec 31, 2025 | -37.89% |
| Sep 30, 2025 | -46.62% |
| Jun 30, 2025 | -41.38% |
| Mar 31, 2025 | -34.49% |
| Dec 31, 2024 | -29.44% |
| Sep 30, 2024 | -23.57% |
| Jun 30, 2024 | -18.25% |
| Mar 31, 2024 | -20.06% |
| Dec 31, 2023 | -23.64% |
| Sep 30, 2023 | -26.76% |